Seffalair Spiromax is a medicine used for the regular treatment of asthma in adults and adolescents above 12 years of age. It is used in patients whose disease is not adequately controlled despite treatment with a combination of a short-acting beta-2 agonist and inhaled corticosteroid. It contains the active substances salmeterol and fluticasone.
Therapeutic Indication
### Therapeutic indication Seffalair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting ?? agonists.
Therapeutic Area (MeSH)
N/AATC Code
R03AK06
ATC Item
salmeterol and fluticasone
Pharmacotherapeutic Group
Drugs for obstructive airway diseases
Active Substance (Summary)
N/AINN / Common Names
N/AEMA Name
Seffalair Spiromax
Medicine Name
Seffalair Spiromax
Aliases
N/ANo risk management plan link.
